Autoimmune Pancreatitis

Sureka, Binit; Rastogi, Archana

doi:10.12659/pjr.900899

Cited by 17 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of immune-related pancreatitis caused by ICIs is rare (CTLA4: 0.9–3%, PD-1: 0.5–1.6%, CTLA4 + PD-1: 1.2–2.1%) [ 6 – 16 ]. Since ICI-induced pancreatitis can be considered an immune-related pancreatitis, it is reasonable to propose that its diagnosis can be based on the diagnostic criteria of autoimmune pancreatitis (AIP) [ 26 , 27 ]; the diagnosis of autoimmune pancreatitis is based on results from these five factors: imaging, serology, histology, extrapancreatic involvement, and perhaps steroid responsiveness. Although the mechanism of immune-induced pancreatitis caused by ICIs is largely unknown, it is postulated that ICIs could unavoidably disturb the balance of autologous tolerance, which could result in some immune-related side effects.…”

Section: Discussionmentioning

confidence: 99%

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Zhang

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta-analysis, which included 9099 patients. Compared with chemotherapy or placebo, the risk ratio (RR) for all-grade lipase elevation after CTLA-4 inhibitor treatment was 1.05 (95% confidence interval (CI): 1.01–2.24, p = 0.047). However, the risk for pancreatitis after ICI treatment in any subgroup was not significantly higher than that after control therapy. In addition, compared with ipilimumab/nivolumab alone, the RR for all-grade and high-grade lipase elevation under combination treatment of nivolumab and ipilimumab was 6.43 (95% CI: 1.43–28.99, p = 0.015) and 6.44 (95% CI: 1.39–29.79, p = 0.017), respectively, and the RR for all-grade amylase elevation under combination treatment was 6.08 (95% CI: 1.51–24.44, p = 0.011). Our meta-analysis has demonstrated that both CTLA-4 inhibitors alone and combination treatment of nivolumab and ipilimumab could increase the risk of amylase or lipase elevation, but not significantly increase the risk of pancreatitis when compared with controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Zhang

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…No entanto, sua baixa disponibilidade e alto custo operacional inviabilizam a utilização rotineira desse exame. Outro fator limitante é a escassez de estudos com intuito de estabelecer a sua precisão diagnóstica na distinção entre PC e PAI (CAI; TAN, 2017;CONTI et al, 2021;SUREKA;RASTOGI, 2017). .…”

Section: Metodologiaunclassified

Pesquisa Comparativa Entre Trabalho Estático E Dinâmico, Relacionado Aos Distúrbios Musculoesqueléticos, Ansiedade E Depressão

Rocha¹,

Marques²,

Fressatto³

et al. 2021

Amplamente: Práticas Cotidianas Em Saúde

View full text Add to dashboard Cite

Direitos para esta edição cedidos pelos autores à Amplamente Cursos e Formação Continuada.Todo o conteúdo deste livro está licenciado sob uma Licença de atribuição Creative Commons. Atribuição-NãoComercial-SemDerivações 4.0 Internacional (CC-BY-NC-ND). Este e-book contém textos escritos por autores de diversos lugares do Brasil e, possivelmente, de fora do país. Todo o conteúdo escrito nos capítulos, assim como correção e confiabilidade são de inteira responsabilidade dos autores, inclusive podem não representar a posição oficial da Editora Amplamente Cursos.

show abstract

“…Type 1 is the pancreatic manifestation of a systemic Immunoglobulin G4-related disease (IgG4-RD); it is associated with increased IgG4 serum concentrations, lymphoplasmacytic infiltrate and phlebitis in the pancreas. Instead, type 2 AIP affects only the pancreas, has normal IgG4 serum concentration and, histologically, shows a neutrophilic inflammation [69]. Hereditary and environmental factors together are thought to induce adaptive immune responses to self-antigens [70].…”

Section: Microbiota and Autoimmune Pancreatitismentioning

confidence: 99%

Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives

Gesualdo

Rizzi

Bonetto

et al. 2020

JCM

View full text Add to dashboard Cite

Gut microbiota represent an interesting worldwide research area. Several studies confirm that microbiota has a key role in human diseases, both intestinal (such as inflammatory bowel disease, celiac disease, intestinal infectious diseases, irritable bowel syndrome) and extra intestinal disorders (such as autism, multiple sclerosis, rheumatologic diseases). Nowadays, it is possible to manipulate microbiota by administering prebiotics, probiotics or synbiotics, through fecal microbiota transplantation in selected cases. In this scenario, pancreatic disorders might be influenced by gut microbiota and this relationship could be an innovative and inspiring field of research. However, data are still scarce and controversial. Microbiota manipulation could represent an important therapeutic strategy in the pancreatic diseases, in addition to standard therapies. In this review, we analyze current knowledge about correlation between gut microbiota and pancreatic diseases, by discussing on the one hand existing data and on the other hand future possible perspectives.

show abstract

Autoimmune Pancreatitis

Cited by 17 publications

References 41 publications

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Pesquisa Comparativa Entre Trabalho Estático E Dinâmico, Relacionado Aos Distúrbios Musculoesqueléticos, Ansiedade E Depressão

Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives

Contact Info

Product

Resources

About